CD73 is highly expressed in several solid tumors including glioblastoma, prostate, and lung cancer, and its inhibition using neutralizing antibodies further improves therapeutic effects of NKG2D-engineered CAR NK cells in a mice model of lung cancer [162]. This evidence concerns the gene KLRK1 and lung cancer.